Serum surfactant protein (SP)-A has been postulated to associate with pulmonary fibrosis, but its role in cigarette smoking-related lung diseases is undefined. SP-A levels in plasma and induced sputum in nonsmokers, smokers with respiratory symptoms (cough and/or phlegm) and symptom-free smokers were assessed using a validated EIA method. A total of 474 current smokers without any diseases or medications were enrolled and followed for 2 yrs with 111 of them succeeding in stopping. Plasma SP-A level was detectable in all subjects and elevated in smokers independently of the symptoms compared to nonsmokers (p=0.001). After 2 yrs of follow-up, the SP-A level was higher in thosewho continued smoking compared to the quitters (p<0.001).PlasmaSP-A levelswere associated with age, smoking history and lung function. Sputum (n=109) SP-A was nondetectable in most nonsmokers, whereas smoking and symptoms increased sputum SP-A highly significantly (p=0.001). In conclusion, SP-A may be involved in pathogenesis of cigarette smoking-related lung diseases. Further studies are needed to elucidate the role of SP-A in chronic obstructive pulmonary disease. Copyright©ERS 2011.
CITATION STYLE
Mazur, W., Toljamo, T., Ohlmeier, S., Vuopala, K., Nieminen, P., Kobayashi, H., & Kinnula, V. L. (2011). Elevation of surfactant protein A in plasma and sputum in cigarette smokers. European Respiratory Journal, 38(2), 277–284. https://doi.org/10.1183/09031936.00110510
Mendeley helps you to discover research relevant for your work.